These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 30626554)

  • 1. Discovery of two novel branched peptidomimetics containing endomorphin-2 and RF9 pharmacophores: Synthesis and neuropharmacological evaluation.
    Zhang T; Han Z; Shi X; Zhao W; Wang Z; Zhang R; Xu B; Zhang M; Zhang Q; Xiao J; Zhu H; Zheng T; Fang Q
    Bioorg Med Chem; 2019 Feb; 27(4):630-643. PubMed ID: 30626554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological characterization of EN-9, a novel chimeric peptide of endomorphin-2 and neuropeptide FF that produces potent antinociceptive activity and limited tolerance.
    Wang ZL; Li N; Wang P; Tang HH; Han ZL; Song JJ; Li XH; Yu HP; Zhang T; Zhang R; Xu B; Zhang MN; Fang Q; Wang R
    Neuropharmacology; 2016 Sep; 108():364-72. PubMed ID: 26970017
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BN-9, a chimeric peptide with mixed opioid and neuropeptide FF receptor agonistic properties, produces nontolerance-forming antinociception in mice.
    Li N; Han ZL; Wang ZL; Xing YH; Sun YL; Li XH; Song JJ; Zhang T; Zhang R; Zhang MN; Xu B; Fang Q; Wang R
    Br J Pharmacol; 2016 Jun; 173(11):1864-80. PubMed ID: 27018797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Central and peripheral modulation of gastrointestinal transit in mice by DN-9, a multifunctional opioid/NPFF receptor agonist.
    Xu B; Guo Y; Zhang M; Zhang R; Chen D; Zhang Q; Xiao J; Xu K; Li N; Qiu Y; Zhu H; Niu J; Zhang X; Fang Q
    Neurogastroenterol Motil; 2020 Aug; 32(8):e13848. PubMed ID: 32281198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Opposite effects of neuropeptide FF on central antinociception induced by endomorphin-1 and endomorphin-2 in mice.
    Wang ZL; Fang Q; Han ZL; Pan JX; Li XH; Li N; Tang HH; Wang P; Zheng T; Chang XM; Wang R
    PLoS One; 2014; 9(8):e103773. PubMed ID: 25090615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Involvement of neuropeptide FF receptors in neuroadaptive responses to acute and chronic opiate treatments.
    Elhabazi K; Trigo JM; Mollereau C; Moulédous L; Zajac JM; Bihel F; Schmitt M; Bourguignon JJ; Meziane H; Petit-demoulière B; Bockel F; Maldonado R; Simonin F
    Br J Pharmacol; 2012 Jan; 165(2):424-35. PubMed ID: 21718302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peripheral and central sites of action for anti-allodynic activity induced by the bifunctional opioid/NPFF receptors agonist BN-9 in inflammatory pain model.
    Zhang R; Xu B; Zhang MN; Zhang T; Wang ZL; Zhao G; Zhao GH; Li N; Fang Q; Wang R
    Eur J Pharmacol; 2017 Oct; 813():122-129. PubMed ID: 28755985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo effects of μ-opioid receptor agonist/δ-opioid receptor antagonist peptidomimetics following acute and repeated administration.
    Anand JP; Kochan KE; Nastase AF; Montgomery D; Griggs NW; Traynor JR; Mosberg HI; Jutkiewicz EM
    Br J Pharmacol; 2018 Jun; 175(11):2013-2027. PubMed ID: 29352503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. VF-13, a chimeric peptide of VD-hemopressin(α) and neuropeptide VF, produces potent antinociception with reduced cannabinoid-related side effects.
    Xu B; Xiao J; Xu K; Zhang Q; Chen D; Zhang R; Zhang M; Zhu H; Niu J; Zheng T; Li N; Zhang X; Fang Q
    Neuropharmacology; 2020 Sep; 175():108178. PubMed ID: 32544481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic administration of the bifunctional opioid/neuropeptide FF receptors agonist BN-9 produced peripheral antinociception in preclinical mouse models of pain.
    Li N; Han ZL; Xu B; Zhang MN; Zhang T; Shi XR; Zhao WD; Guo YY; Zhang QQ; Fang Q
    Eur J Pharmacol; 2018 Oct; 837():53-63. PubMed ID: 30172787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dynorphinergic mechanism mediating endomorphin-2-induced antianalgesia in the mouse spinal cord.
    Wu HE; Sun HS; Darpolar M; Leitermann RJ; Kampine JP; Tseng LF
    J Pharmacol Exp Ther; 2003 Dec; 307(3):1135-41. PubMed ID: 14557378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo pharmacological characterization of SoRI 9409, a nonpeptidic opioid mu-agonist/delta-antagonist that produces limited antinociceptive tolerance and attenuates morphine physical dependence.
    Wells JL; Bartlett JL; Ananthan S; Bilsky EJ
    J Pharmacol Exp Ther; 2001 May; 297(2):597-605. PubMed ID: 11303048
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of opioid receptors in the spinal antinociceptive effects of neuropeptide FF analogues.
    Gouardères C; Jhamandas K; Sutak M; Zajac JM
    Br J Pharmacol; 1996 Feb; 117(3):493-501. PubMed ID: 8821539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of neuropeptide FF (NPFF)-induced hypothermia and anti-morphine analgesia by RF9, a new selective NPFF receptors antagonist.
    Fang Q; Wang YQ; He F; Guo J; Guo J; Chen Q; Wang R
    Regul Pept; 2008 Apr; 147(1-3):45-51. PubMed ID: 18276024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. OFP011 Cyclic Peptide as a Multifunctional Agonist for Opioid/Neuropeptide FF Receptors with Improved Blood-Brain Barrier Penetration.
    Zhang M; Xu B; Li N; Zhang R; Zhang Q; Chen D; Rizvi SFA; Xu K; Shi Y; Yu B; Fang Q
    ACS Chem Neurosci; 2022 Nov; 13(21):3078-3092. PubMed ID: 36262082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RF313, an orally bioavailable neuropeptide FF receptor antagonist, opposes effects of RF-amide-related peptide-3 and opioid-induced hyperalgesia in rodents.
    Elhabazi K; Humbert JP; Bertin I; Quillet R; Utard V; Schneider S; Schmitt M; Bourguignon JJ; Laboureyras E; Ben Boujema M; Simonnet G; Ancel C; Simonneaux V; Beltramo M; Bucher B; Sorg T; Meziane H; Schneider E; Petit-Demoulière B; Ilien B; Bihel F; Simonin F
    Neuropharmacology; 2017 May; 118():188-198. PubMed ID: 28288815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis, modeling, and pharmacological evaluation of UMB 425, a mixed μ agonist/δ antagonist opioid analgesic with reduced tolerance liabilities.
    Healy JR; Bezawada P; Shim J; Jones JW; Kane MA; MacKerell AD; Coop A; Matsumoto RR
    ACS Chem Neurosci; 2013 Sep; 4(9):1256-66. PubMed ID: 23713721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intracerebroventricular administration of CYX-6, a potent μ-opioid receptor agonist, a δ- and κ-opioid receptor antagonist and a biased ligand at μ, δ & κ-opioid receptors, evokes antinociception with minimal constipation and respiratory depression in rats in contrast to morphine.
    Imam MZ; Kuo A; Ghassabian S; Cai Y; Qin Y; Li T; Smith MT
    Eur J Pharmacol; 2020 Mar; 871():172918. PubMed ID: 31958457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endogenous mammalian RF-amide peptides, including PrRP, kisspeptin and 26RFa, modulate nociception and morphine analgesia via NPFF receptors.
    Elhabazi K; Humbert JP; Bertin I; Schmitt M; Bihel F; Bourguignon JJ; Bucher B; Becker JA; Sorg T; Meziane H; Petit-Demoulière B; Ilien B; Simonin F
    Neuropharmacology; 2013 Dec; 75():164-71. PubMed ID: 23911743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential modulation of mu- and delta-opioid antinociception by neuropeptide FF receptors in young mice.
    Desprat C; Zajac JM
    Neuropeptides; 1997 Feb; 31(1):1-7. PubMed ID: 9574828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.